Choudhury R, Bahadi C, Ray I, Dash P, Pattanaik I, Mishra S
Cell Commun Signal. 2024; 22(1):529.
PMID: 39487435
PMC: 11531143.
DOI: 10.1186/s12964-024-01898-y.
Bojarska J, Breza M, Borowiecki P, Madura I, Kaczmarek K, Ziora Z
R Soc Open Sci. 2024; 11(10):40962.
PMID: 39386982
PMC: 11462612.
DOI: 10.1098/rsos.240962.
Atalay P, Ozpolat B
Cancers (Basel). 2024; 16(3).
PMID: 38339286
PMC: 10854964.
DOI: 10.3390/cancers16030535.
Naufal M, Hermawati E, Syah Y, Hidayat A, Hidayat I, Al-Anshori J
ACS Omega. 2024; 9(4):4186-4209.
PMID: 38313530
PMC: 10832052.
DOI: 10.1021/acsomega.3c04749.
Hu S, Trieb M, Huang R, Tamalunas A, Keller P, Gotz M
Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(2):1219-1231.
PMID: 37658212
PMC: 10791718.
DOI: 10.1007/s00210-023-02664-6.
Synthesis and Anticancer Activity of Novel Dual Inhibitors of Human Protein Kinases CK2 and PIM-1.
Winska P, Wielechowska M, Koronkiewicz M, Borowiecki P
Pharmaceutics. 2023; 15(7).
PMID: 37514177
PMC: 10385865.
DOI: 10.3390/pharmaceutics15071991.
Pim Kinases: Important Regulators of Cardiovascular Disease.
Nock S, Karim E, Unsworth A
Int J Mol Sci. 2023; 24(14).
PMID: 37511341
PMC: 10380471.
DOI: 10.3390/ijms241411582.
Combining machine learning and structure-based approaches to develop oncogene PIM kinase inhibitors.
Almukadi H, Jadkarim G, Mohammed A, Almansouri M, Sultana N, Shaik N
Front Chem. 2023; 11:1137444.
PMID: 36970406
PMC: 10036574.
DOI: 10.3389/fchem.2023.1137444.
Design, synthesis and cytotoxic evaluation of novel bis-thiazole derivatives as preferential Pim1 kinase inhibitors with and study.
Al-Sanea M, Nasr T, Bondock S, Gawish A, Mohamed N
J Enzyme Inhib Med Chem. 2023; 38(1):2166936.
PMID: 36728746
PMC: 9897788.
DOI: 10.1080/14756366.2023.2166936.
Exploring metabolism in scleroderma reveals opportunities for pharmacological intervention for therapy in fibrosis.
Cantanhede I, Liu H, Balbuena Rodriguez V, Shiwen X, Ong V, Denton C
Front Immunol. 2022; 13:1004949.
PMID: 36304460
PMC: 9592691.
DOI: 10.3389/fimmu.2022.1004949.
Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors.
Katsuta E, Gil-Moore M, Moore J, Yousif M, Adjei A, Ding Y
Int J Oncol. 2022; 61(4).
PMID: 35920189
PMC: 9387562.
DOI: 10.3892/ijo.2022.5404.
Targeting Host PIM Protein Kinases Reduces Mayaro Virus Replication.
Sugasti-Salazar M, Campos D, Valdes-Torres P, Galan-Jurado P, Gonzalez-Santamaria J
Viruses. 2022; 14(2).
PMID: 35216015
PMC: 8878588.
DOI: 10.3390/v14020422.
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.
Kunder R, Velyunskiy M, Dunne S, Cho B, Kanojia D, Begg L
Cell Chem Biol. 2021; 29(3):358-372.e5.
PMID: 34525344
PMC: 8901784.
DOI: 10.1016/j.chembiol.2021.08.011.
Anti-Inflammatory Effects of the Novel PIM Kinase Inhibitor KMU-470 in RAW 264.7 Cells through the TLR4-NF-κB-NLRP3 Pathway.
Baek H, Min H, Hong V, Kwon T, Park J, Lee J
Int J Mol Sci. 2020; 21(14).
PMID: 32698512
PMC: 7403980.
DOI: 10.3390/ijms21145138.
Discovery and Structure-Activity Relationship Study of ()-5-Methylenethiazolidin-4-one Derivatives as Potent and Selective Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.
Manz T, Sivakumaren S, Ferguson F, Zhang T, Yasgar A, Seo H
J Med Chem. 2020; 63(9):4880-4895.
PMID: 32298120
PMC: 7292230.
DOI: 10.1021/acs.jmedchem.0c00227.
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
Kennedy S, ONeill M, Cunningham D, Morris P, Toomey S, Blanco-Aparicio C
Oncogene. 2020; 39(14):3028-3040.
PMID: 32042115
PMC: 7118022.
DOI: 10.1038/s41388-020-1202-y.
PIM kinases facilitate lentiviral evasion from SAMHD1 restriction via Vpx phosphorylation.
Miyakawa K, Matsunaga S, Yokoyama M, Nomaguchi M, Kimura Y, Nishi M
Nat Commun. 2019; 10(1):1844.
PMID: 31015445
PMC: 6479052.
DOI: 10.1038/s41467-019-09867-7.
STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells.
Ribeiro D, Melao A, van Boxtel R, Santos C, Silva A, Silva M
Blood Adv. 2018; 2(17):2199-2213.
PMID: 30185437
PMC: 6134214.
DOI: 10.1182/bloodadvances.2018021063.
Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Lee M, Lee K, Min A, Kim J, Kim S, Jang H
Cancer Res Treat. 2018; 51(2):451-463.
PMID: 29879757
PMC: 6473293.
DOI: 10.4143/crt.2017.341.
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman L, Mruthyunjayappa S, Waters A, Garner E, Aye J, Stewart J
Oncotarget. 2018; 9(32):22665-22679.
PMID: 29854306
PMC: 5978256.
DOI: 10.18632/oncotarget.25205.
